Malaria vaccine: A bright prospect for elimination of malaria

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 819-822

  Bairwa, Mohan ^a   Rajput, Meena ^a   Khanna, Pardeep ^a   Rohilla, Ravi ^a   Verma, Ramesh ^a   Chawla, Sumit ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

AMA1; Control; Elimination; Falciparum; Malaria; RTS; S vaccine; Sporozoite

Indexed keywords

ATYPICAL MEMBRANE PROTEIN 1 VACCINE; CIRCUMSPOROZOITE PROTEIN; HEPATITIS B SURFACE ANTIGEN; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; SPOROZOITE VACCINE; UNCLASSIFIED DRUG; VACCINE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HOST PARASITE INTERACTION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INSECTICIDE RESISTANCE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PARASITE VECTOR; PLASMODIUM FALCIPARUM; PROTEIN FUNCTION; SOCIAL CLASS; VACCINE PRODUCTION;

HUMANS; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; PROTOZOAN PROTEINS; SPOROZOITES;

EID: 84863678922     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20145     Document Type: Note

References (24)

1. Koram KA, Gyan BA. Malaria vaccine development: an endemic country perspective. Hum Vaccin 2010; 6:12-6; PMID:19806020; http://dx.doi. org/10.4161/hv.6.1.9605.
2. Areválo-Herrera M, Chitnis C, Herrera S. Current status of Plasmodium vivax vaccine. Hum Vaccin 2010; 6:124-32; PMID:20009526; http://dx.doi. org/10.4161/hv.6.1.9931.
3. Vaughan AM, Wang R, Kappe SHI. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010; 6:107-13; PMID:19838068; http://dx.doi.org/10.4161/hv.6.1.9654.
4. Sinden RE. A biologist's perspective on malaria vaccine development. Hum Vaccin 2010; 6:3-11; PMID:19946205; http://dx.doi.org/10.4161/hv.6.1.9604.
5. Doolan DL. Special issue on malaria vaccine development. Hum Vaccin 2010; 6:2; http://dx.doi.org/10.4161/hv.6.1.10703.
6. WHO releases new malaria guidelines for treatment and procurement of medicines. www.who.int/mediacentre/ news/releases/2010/malaria-20100308/en/ index.html
7. Leitner WW, Bergmann-Leitner ESB, Angov E. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Malar J 2010; 9:1-12; PMID:20043863; http:// dx.doi.org/10.1186/1475-2875-9-145.
8. Chauhan VS. A step forward in malaria vaccine development. Curr Sci 2008; 94:973. (Pubitemid 351705372)
9. WHO. Disease Burden & Status of Malaria Control. http://www.who.int/ vaccine-research/Malaria/en/index.html
10. Biswas S, Dicks MDJ, Long CA, Remarque EJ, Siani L, Colloca S. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of plasmodium falciparum AMA1. PLoS ONE 2011;6[16 pages]. Available from:http://plosone.org.
11. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193:673-5; PMID:781840; http://dx.doi.org/10.1126/science.781840.
12. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010; 6:97-106; PMID:19946222; http:// dx.doi.org/10.4161/hv.6.1.10396.
13. Limbach K, Aguiar J, Gowda K, Patterson N, Albot E, Sedegah M, et al. Identification of two new protective preerythrocytic malaria vaccine antigen candidates. Malar J 2011; 10:1-11; PMID:21214892; http://dx.doi.org/10.1186/ 1475-2875-10-65.
14. Bruder JT, Angov E, Limbach KJ, Richie TL. Molecular vaccines for malaria. Hum Vaccin 2010; 6:54-77; PMID:20061792; http://dx.doi. org/10.4161/hv.6.1.10463.
15. Anders RF, Adda CG, Foley M, Norton RS. Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum Vaccin 2010; 6:39-53; PMID:20061790; http://dx.doi. org/10.4161/hv.6.1.10712.
16. Kim TS, Kim HH, Kim JY, Kong Y, Na BK, Lin K, et al. Comparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, Myanmar. Malar J 2011; 10:228; PMID:21819610; http://dx.doi. org/10.1186/1475-2875-10-228.
17. Elis RD, Fay MP, Sagara I, Dicko A, Miura K, Guindo MA, et al. Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine. Malar J 2011; 10:1-7; PMID:21214892.
18. Human vaccines news. World's largest malaria vaccine trial now underway. Hum Vaccin 2009; 5:785-6.
19. White MT, Griffin JT, Drakeley CJ, Ghani AC. Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J 2010; 9:1-9; PMID:20043863; http://dx.doi.org/10.1186/ 1475-2875-9-82.
20. WHO. Most advanced malaria vaccine candidate and timing for policy recommendations. www.who. int/vaccine-research/diseases/malaria/vaccine- candidate- policy/en/index.html
21. Ojakaa DI, Ofware P, Machira YW, Yamo E, Collymore Y, Nguz AB, et al. Community perceptions of malaria and vaccines in the South Coast and Busia regions of Kenya. Malar J 2011; 10:2-11; PMID:21214940; http://dx.doi.org/10. 1186/1475-2875-10-147.
22. The RTS. S Clinical Trials Partnership. The RTS,S clinical trials partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 10:1-13.
23. Chilengi R, Gitaka J. Is vaccine the magic bullet for malaria elimination? A reality check. Malar J 2010; 9:1-8; PMID:20043863; http://dx.doi. org/10.1186/1475-2875-9-S3-S1.
24. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS MEDICINE. 2012;9[20 pages]. Available from:http://plosmedicine. org.